FCS patients, like Kara Hill, have to deal with a variety of challenges while fighting the disorder. Among these daily struggles are severe dietary restrictions and a gerneal understanding of the disease from others.
#LivingWithFCS#FCS#FCSAwareness#RareDisease
Friday, Nov. 6 is FCS Awareness Day. FCS causes severely high triglycerides and risk of life-threatening pancreatitis, often missed for years. Through the work of the Foundation, weโre shining a light on the signs.
https://t.co/tvUP7WJ7cf
#FCSAwarenessDay
@ActionFCS is running a 10g Fat Challenge to mark FCS Awareness Day โ spend a day eating no more than 10g of fat, and experience first-hand what living with FCS is like every single day. Check them out ๐
https://t.co/0o2mWuOLbo
#FCSAwarenessDay#10gFatChallenge@TGDisorders
This Friday, Nov. 6, is FCS Awareness Day. @TGDisorders is sharing the voices of patients and caregivers living with FCS, a rare, inherited disorder that causes extremely high triglycerides and a constant risk of severe pancreatitis.
Read the release: https://t.co/AZbdyS0rUU
Living with FCS means more than following a strict diet. The risk of pancreatitis can make everyday food choices and social gatherings challenging. Qingyang Li shares his experiences living with FCS.
#FCSAwareness#PatientStories#LivingwithFCS
Drawing on lived experience, clinical expertise, advocacy perspectives, and published evidence, โHidden in Plain Sightโ calls for clear information, coordinated care, and meaningful support for people living with very high triglycerides from day one. Developed with support from @ionispharma.
https://t.co/qEGdcTxiKe
#TriglyceridesinPlainSight #VeryHighTriglycerides
As an FCS caregiver, Lynne Saremi knows the daily challenges of FCS through her husband Fredโs journey. She believes hope, continued research, and greater awareness can lead to breakthroughs for the FCS community. ๐
#FCSAwareness#LivingWithFCS#CaregiverLife
Ahead of FCS Awareness Day on November 6, we're sharing the stories of those living with FCS. Patient Rick Lunceford shares what he wishes more people understood about this rare disorder and its daily challenges. ๐
#FCSAwareness#PatientStories#LivingWithFCS
Severe Hypertriglyceridemia (sHTG) is a condition in which triglyceride levels reach 500 mg/dL or higher. Understanding your numbers is the first step toward lower risk and better health.
Learn more: https://t.co/4hByXFHflV
#sHGT#HealthAwareness#TGDisorders#Triglycerides
Multifactorial Chylomicronemia Syndrome (MCS) is a disorder in which a combination of genetic predisposition and secondary factors leads to elevated triglyceride levels.
Learn more: https://t.co/xQG9NtHmSN
#MCS#TGDisorders#Triglycerides
The 3rd Annual FCS Summit brought our amazing FCS community together in Milwaukee for learning, laughter, and shared experiences.
From inspiring presentations to meaningful conversations, this Summit reminded us how strong we are when we come together.
#LivingWithFCS
FCS is a disorder in which the body cannot properly break down triglycerides. The Foundation for Triglyceride Disorders helps connect patients with caregivers and clinicians to provide education, resources, and community.
https://t.co/srGqlGY54I
#FCS#TGDisorders#livingwithFCS
Have you experienced pancreatitis due to sHTG? @ArrowheadPharma wants your voice on its new Lived Experience Council! If you're 18+, U.S.-based, and English-speaking, email [email protected] to learn more.
๐ https://t.co/Np9rImPexF
#sHTG#PatientVoice
What an incredible weekend at the FCS Summit in Milwaukee! ๐
We learned, shared, connected, and strengthened a community united by a shared mission: improving the lives of those living with FCS. Thank you to everyone who made it to the summit!
#LivingWithFCS#TGDisorders
Dennis knows exactly what he's looking forward to at the 2026 #FCS Foundation Patient & Caregiver Summit: seeing familiar faces and getting information and resources built specifically for the FCS community.
If you're living with FCS, this one's for you. https://t.co/ESuKYRmtoS
Breaking News: At the European Society of Cardiology Congress (ESC), we presented Phase 3 SHASTA-3 & SHASTA-4 data demonstrating our investigational siRNA therapy reduced acute pancreatitis events in patients with severe hypertriglyceridemia.
Learn more: https://t.co/D8ES58MCi2